よむ、つかう、まなぶ。
05資料2-1森野委員提出資料（RSウイルス母子免疫ワクチンと抗体製剤ファクトシート） (47 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64997.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第32回 10／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
respiratory syncytial virus disease, May 2025. https://iris.who.int/server/api/core/bitstreams/96ec533ade56-4e1a-8e01-420afda0b683/content (accessed 2025/10/6).
63.
独立行政法人医薬品医療機器総合機構. アブリスボ筋注用審議結果報告書. 2024.
https://www.pmda.go.jp/drugs/2024/P20240325002/672212000_30600AMX00014_A100_2.pdf (accessed
2025/4/28).
64.
McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a
prefusion-specific neutralizing antibody. Science 2013; 340(6136): 1113-7.
65.
Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. Architecture of respiratory syncytial virus
revealed by electron cryotomography. Proc Natl Acad Sci U S A 2013; 110(27): 11133-8.
66.
Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specific antibodies determine the
magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015; 7(309): 309ra162.
67.
Karron RA. Vaccines.
Respiratory Syncytial Virus Vaccines. 7th ed. Philadelphia: Saunders;
2018: 943-9.
68.
Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent
RSV Illness in Infants. N Engl J Med 2023; 388(16): 1451-64.
69.
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and
update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and
Committee of Fetus and Newborn. Pediatrics 1998; 102(5): 1211-6.
70.
独立行政法人医薬品医療機器総合機構. パリビズマブ（遺伝子組換え）審議結果報告書. 2024.
https://www.pmda.go.jp/drugs/2024/P20240422002/670227000_22400AMX01366_A100_1.pdf (accessed
2025/4/28).
71.
Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding
to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281(33): 23514-24.
72.
独立行政法人医薬品医療機器総合機構. ニルセビマブ審議結果報告書. 2024.
https://www.pmda.go.jp/drugs/2024/P20240705003/670227000_30600AMX00127_A100_2.pdf (accessed
2025/4/28).
73.
Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-
Preterm and Term Infants. N Engl J Med 2022; 386(9): 837-46.
74.
Walsh EE, Falsey AR, Scott DA, et al. A Randomized Phase 1/2 Study of a Respiratory Syncytial
Virus Prefusion F Vaccine. J Infect Dis 2022; 225(8): 1357-66.
75.
Simões EAF, Center KJ, Tita ATN, et al. Prefusion F Protein-Based Respiratory Syncytial Virus
Immunization in Pregnancy. N Engl J Med 2022; 386(17): 1615-26.
76.
Simões EAF, Pahud BA, Madhi SA, et al. Efficacy, Safety, and Immunogenicity of the MATISSE
(Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion
F Protein Vaccine Trial. Obstet Gynecol 2025; 145(2): 157-67.
77.
独立行政法人医薬品医療機器総合機構. アブリスボ筋注用審議結果報告書. 2023.
https://www.pmda.go.jp/drugs/2024/P20240112002/672212000_30600AMX00014_A100_1.pdf (accessed
2025/4/28).
47
63.
独立行政法人医薬品医療機器総合機構. アブリスボ筋注用審議結果報告書. 2024.
https://www.pmda.go.jp/drugs/2024/P20240325002/672212000_30600AMX00014_A100_2.pdf (accessed
2025/4/28).
64.
McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a
prefusion-specific neutralizing antibody. Science 2013; 340(6136): 1113-7.
65.
Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. Architecture of respiratory syncytial virus
revealed by electron cryotomography. Proc Natl Acad Sci U S A 2013; 110(27): 11133-8.
66.
Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specific antibodies determine the
magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015; 7(309): 309ra162.
67.
Karron RA. Vaccines.
Respiratory Syncytial Virus Vaccines. 7th ed. Philadelphia: Saunders;
2018: 943-9.
68.
Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent
RSV Illness in Infants. N Engl J Med 2023; 388(16): 1451-64.
69.
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and
update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and
Committee of Fetus and Newborn. Pediatrics 1998; 102(5): 1211-6.
70.
独立行政法人医薬品医療機器総合機構. パリビズマブ（遺伝子組換え）審議結果報告書. 2024.
https://www.pmda.go.jp/drugs/2024/P20240422002/670227000_22400AMX01366_A100_1.pdf (accessed
2025/4/28).
71.
Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding
to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281(33): 23514-24.
72.
独立行政法人医薬品医療機器総合機構. ニルセビマブ審議結果報告書. 2024.
https://www.pmda.go.jp/drugs/2024/P20240705003/670227000_30600AMX00127_A100_2.pdf (accessed
2025/4/28).
73.
Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for Prevention of RSV in Healthy Late-
Preterm and Term Infants. N Engl J Med 2022; 386(9): 837-46.
74.
Walsh EE, Falsey AR, Scott DA, et al. A Randomized Phase 1/2 Study of a Respiratory Syncytial
Virus Prefusion F Vaccine. J Infect Dis 2022; 225(8): 1357-66.
75.
Simões EAF, Center KJ, Tita ATN, et al. Prefusion F Protein-Based Respiratory Syncytial Virus
Immunization in Pregnancy. N Engl J Med 2022; 386(17): 1615-26.
76.
Simões EAF, Pahud BA, Madhi SA, et al. Efficacy, Safety, and Immunogenicity of the MATISSE
(Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion
F Protein Vaccine Trial. Obstet Gynecol 2025; 145(2): 157-67.
77.
独立行政法人医薬品医療機器総合機構. アブリスボ筋注用審議結果報告書. 2023.
https://www.pmda.go.jp/drugs/2024/P20240112002/672212000_30600AMX00014_A100_1.pdf (accessed
2025/4/28).
47